HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

In a letter to FDA, Johnson & Johnson and Energizer propose a study exploring questions FDA has raised about previous studies on sun-protection products with SPF values greater than 50. Separately, Reckitt Benckiser divests Indian personal-care brands and Revlon and Givaudan report sales and earnings for fiscal 2011. More news in brief.

You may also be interested in...



P&G Slashes Guidance, Promises Sharper Focus, Bigger Innovations

P&G will launch “bigger” products, pursue a more balanced growth objective, firm says during investor conference June 20, the same day the firm’s stock slipped on slashed guidance for the fourth quarter and fiscal year.

Reckitt Reorganizes To Develop Health Care, Emerging Markets

Reckitt Benckiser reorganizes to emphasize consumer health care and emerging markets, both high growth areas for the firm. CEO Rakesh Kapoor says move addresses “fundamental organizational imbalance.” Firm’s fiscal 2011 total net revenues totaled $15 billion.

P&G Beauty Growth Abroad Offsets Challenges In U.S. In Q4

Growth of Procter & Gamble's beauty business in developing markets kept the unit afloat in the fourth quarter and fiscal year 2011, despite challenges in the U.S. including the recall of Olay UV products and a continuing rebuild of Pantene equity.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017970

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel